ALK and neoplasm: In 2021, Jiang et al. designed Alectinib-degrader SIAIS001, which exhibited superior cytolytic activity compared to Alectinib and good oral bioavailability.402 At the same year, Li et al. constructed B3 and validated it in vivo, which demonstrated improved anticancer activity compared to the parent inhibitor.402 In 2023, an oral degrader, CPD-1224, successfully degraded ALK L1196M/G1202R, slowing tumor growth in vivo, while the ALK inhibitor Lorlatinib had no effect.403